Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions

The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has shown dramatic effects in patients with non‐small cell lung cancer (NSCLC) harboring ROS1 fusion genes. However, patients inevitably develop resistance to this agent. Therefore, a new treatment strategy is required for lung tumors with ROS1 fus...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Yuka, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tomida, Shuta, Makimoto, Go, Watanabe, Hiromi, Kudo, Kenichiro, Matsumoto, Shingo, Umemura, Shigeki, Goto, Koichi, Ichihara, Eiki, Ninomiya, Takashi, Kubo, Toshio, Sato, Akiko, Hotta, Katsuyuki, Tabata, Masahiro, Toyooka, Shinichi, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172052/
https://www.ncbi.nlm.nih.gov/pubmed/30053332
http://dx.doi.org/10.1111/cas.13752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172052/
https://www.ncbi.nlm.nih.gov/pubmed/30053332
http://dx.doi.org/10.1111/cas.13752

Ejemplares similares